Related Experiment Videos
Levamisole in rheumatoid arthritis: a comparison with D-penicillamine
Abstract:
Levamisole (150 mg 3 days/week) was compared with D-penicillamine (250 mg increments at 2--3 monthly intervals) in a single, blind independent observer trial of 1 years' duration in 32 patients with rheumatoid arthritis. The clinical responses, evident after 3 months, were comparable and significant. Six patients on levamisole and 4 on penicillamine withdrew due to side effects. In the subsequent open study 3 of 8 patients continued on levamisole for up to 4 years, while 6 of 9 remained on penicillamine. The findings are compared with those of other trials.
Insights
Levamisole and D-penicillamine showed comparable clinical responses in rheumatoid arthritis patients over one year. Levamisole treatment was associated with fewer side effects, allowing longer patient adherence in subsequent studies.
Area of Science:
- Immunology
- Rheumatology
- Clinical Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Disease-modifying antirheumatic drugs (DMARDs) are crucial for RA management.
- Levamisole and D-penicillamine are established immunomodulatory agents used in RA treatment.
Purpose of the Study:
- To compare the efficacy and tolerability of levamisole versus D-penicillamine in rheumatoid arthritis patients.
- To evaluate long-term treatment outcomes and side effect profiles of these two DMARDs.
Main Methods:
- A single-blind, independent observer trial involving 32 RA patients.
- Patients received either levamisole (150 mg, 3 days/week) or D-penicillamine (250 mg increments) for one year.
- Clinical responses and adverse events were monitored.
Main Results:
- Comparable and significant clinical responses were observed for both levamisole and D-penicillamine after 3 months.
- Six patients on levamisole and 4 on D-penicillamine withdrew due to side effects.
- In a subsequent open study, 3/8 patients continued levamisole up to 4 years, while 6/9 continued D-penicillamine.
Conclusions:
- Levamisole and D-penicillamine demonstrate similar short-term efficacy in treating rheumatoid arthritis.
- Levamisole may offer a better side effect profile, potentially leading to improved long-term adherence.
- Further comparative studies are warranted to confirm long-term benefits and safety.